Table 1.

Characteristics of patients at study entry by treatment group

CharacteristicsPrednisone Group 1IVCY Group 2CsA Group 3
Gender (female/male)12/312/311/1
Age (yr; median [range])40 (20 to 58)41 (17 to 60)34 (13 to 56)
Race/ethnicity (white/other)a3/128/71/11
Duration of LMN before study entry (mo; median [range])11.5 (3 to 120)7 (2 to 24)6 (1 to 16)
GFR (ml/min per 1.73 m2; median [range])80 (32 to 112)80 (61 to 112)89 (68 to 189)
Proteinuria (g/d; median [range])5.7 (2.8 to 10.6)5.0 (2.7 to 15.4)5.8 (2.7 to 13.8)
Serum albumin (g/dl; median [range])2.7 (1.3 to 3.6)3.0 (1.6 to 3.6)2.5 (1.9 to 3.3)
Cholesterol (mg/dl; median [range])297 (207 to 501)268 (173 to 339)279 (194 to 631)
Hematocrit (%; median [range])36 (31 to 45)38 (33 to 45)36 (27 to 42)
Anti dsDNA antibodies (patients)432
Low C3 complement (patients)111
Low C4 complement (patients)201
  • a White refers to non-Hispanic white patients, and other refers to black and Hispanic patients.